Moban Related Published Studies
Well-designed clinical trials related to Moban (Molindone)
D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. [1996.10]
A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. [1990.10]
Well-designed clinical trials possibly related to Moban (Molindone)
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum
Disorders study. [2012]
Double-blind maintenance safety and effectiveness findings from the Treatment of
Early-Onset Schizophrenia Spectrum (TEOSS) study. [2010]
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. [2008.11]
Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. [2006.09]
Expected incidence of tardive dyskinesia associated with atypical antipsychotics. [2000]
L-tyrosine pharmacotherapy of schizophrenia: preliminary data. [1994.02]
Thioridazine improves affective symptoms in schizophrenic patients. [1993]
Other research related to Moban (Molindone)
Molindone for schizophrenia and severe mental illness. [2007.01.24]
Molindone for schizophrenia and severe mental illness. [2000]
Treatment of clozapine- and molindone-induced agranulocytosis with granulocyte colony-stimulating factor. [1993.10]
The use of molindone in the treatment of psychotic and delirious patients infected with the human immunodeficiency virus. Case reports. [1993.01]
Neuroleptic malignant syndrome possibly caused by molindone hydrochloride. [1991.10]
Polydipsia and hyponatremia induced by multiple neuroleptics but not molindone. [1990.04]
Relation of serum molindone levels to serum prolactin levels and antipsychotic response. [1989.10]
Reinstitution of neuroleptic treatment with molindone in a patient with a history of neuroleptic malignant syndrome. [1989.09]
Molindone hydrochloride: a review of laboratory and clinical findings. [1989.08]
Other possibly related research studies
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. [2005.01.01]
Tissue distribution of molidone in a multidrug overdose. [2004.09]
Antipsychotic-induced weight gain: a comprehensive research synthesis. [1999.11]
Psychosis during pregnancy: treatment considerations. [1997.09]
Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. [1995.08]
Basal ganglia iron in tardive dyskinesia: an MRI study. [1994.01.01]
Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen. [1990.12]
Antipsychotic medication and seizures: a review. [2003.07]
Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. [2002.11]
[Body weight changes and psychotropic drug treatment: neuroleptics] [2001.05]
Weight gain associated with antipsychotic drugs. [1999]
Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. [1998.03]
Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. [1996.05]
Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs. [1995.06]
The clinical impact of reported variance in potency of antipsychotic agents. [1995.04]
Weight gain associated with neuroleptic medication: a review. [1995]
Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. [1994.11]
Fluoxetine ingestion: a one year retrospective study. [1990.04]
Which atypical antipsychotics are identified by screening tests? [1989.06]
Successful use of clozapine in a patient with a history of neuroleptic malignant syndrome. [1989.06]
The possible role of dopamine autoreceptors in neuroleptic atypicality. [1988.03]
Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. [2006.11]
Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. [2006.01.25]
Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. [2007.08]
Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. [2008.10]
Treatment of early-onset schizophrenia. [2010.07]
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. [2010.06]
Atypical antipsychotics for psychosis in adolescents. [2013]
|
